{"id":"W4281627373","doi":"10.1016/s0140-6736(22)00467-6","title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","year":2022,"lang":"en","type":"article","venue":"The Lancet","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":387,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; University of Alberta; University of Calgary","funders":"UCB Pharma; Pfizer Japan; Samsung; Genentech; Norgine; Sun Pharma; Eli Lilly and Company; Ono Pharmaceutical; Daiichi-Sankyo; Mitsubishi Tanabe Pharma Corporation; Celltrion; Mylan; Celgene; Pfizer; Biogen; EA Pharma Co., Ltd.; Gilead Sciences; AbbVie; Kyorin Pharmaceutical; Sanofi; Tillotts Pharma; Allergan; AstraZeneca; Seres Therapeutics; Nichi-Iko Pharmaceutical; Amgen","keywords":"Medicine; Placebo; Crohn's disease; Internal medicine; Population; Clinical trial; Randomized controlled trial; Disease; Physical therapy; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005365558,0.000620934,0.002057105,0.000237469,0.0002519957,0.001429536,0.0004978001,0.001562957,0.002682799],"category_scores_gemma":[0.004448838,0.0002098103,0.002573635,0.0003759481,0.0005569941,0.0009951845,0.0005245716,0.004371747,0.00058005],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001039675,"about_ca_system_score_gemma":0.001280413,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008647812,"about_ca_topic_score_gemma":0.002722467,"domain_scores_codex":[0.9987739,0.00062372,0.00006854247,0.00009572831,0.0002224666,0.0002157059],"domain_scores_gemma":[0.9962835,0.001679401,0.0007667116,0.0002420706,0.0002826306,0.000745651],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3854617,0.003332801,0.006306269,0.003937399,0.004158751,0.0001515861,0.0002094829,0.001767779,0.005818648,0.001925234,0.03869498,0.5482354],"study_design_scores_gemma":[0.7142577,0.1067078,0.06119084,0.002226032,0.008887088,0.0006198057,0.00021873,0.001718098,0.003320637,0.006384013,0.09432297,0.000146248],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.56948,0.3510542,0.002422256,0.04707399,0.004361302,0.001172991,0.005321096,0.0004005953,0.01871359],"genre_scores_gemma":[0.8596732,0.09209505,0.006274489,0.02616197,0.003486303,0.0009936426,0.005120737,0.0001456177,0.006049092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005365558,"threshold_uncertainty_score":0.0283761,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04230221700299876,"score_gpt":0.3244452588349456,"score_spread":0.2821430418319469,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}